Researchers have discovered a new strategy to overcome docetaxel resistance in advanced prostate cancer patients, which may improve the efficacy of chemotherapy and prolong overall survival. The approach involves inhibiting cholesterol and lipid biosynthesis, reinducing sensitivity to the drug docetaxel.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with advanced small cell bladder cancer and small cell/neuroendocrine prostate cancer. The study found that the combination treatment resul...
A recent study has uncovered a genetic variant in the PSA gene that is associated with aggressive prostate cancer. This finding could lead to the development of a novel point-of-care device that can identify high-risk patients with low blood PSA levels, enabling early detection and treatment.
A new study by Cedars-Sinai reveals that significant percentages of older men with intermediate- and high-risk prostate cancers are being subjected to aggressive treatments that may not extend their lives, highlighting the need for a more personalized approach to cancer treatment. The study suggests that better estimation, communicatio...
A new strategy for treating prostate cancer has been developed by blocking the GP130 signalling pathway, contrary to current medical understanding. The study found that activating GP130 in prostate cells reduces tumour growth and stimulates the immune system to fight cancer cells.
A comprehensive analysis of 52,000 men with prostate cancer treatment found substantial long-term risks of urinary and sexual complications. Men treated with radiotherapy faced a threefold risk of bladder cancer diagnosis, while those who underwent prostatectomy had a sixfold increased risk of complications.
Researchers have identified 22 pesticides consistently linked to prostate cancer incidence across US counties, including 2,4-D. Four pesticides are also associated with increased prostate cancer mortality rates.
Researchers developed an AI model that can identify and measure aggressive prostate cancer lesions with high accuracy. The model's estimates of tumor size were associated with the likelihood of cancer recurrence or metastasis.
A new discovery by Cold Spring Harbor Laboratory's Lloyd Trotman suggests that menadione, a precursor to vitamin K, can slow prostate cancer progression in mice. The supplement depletes a lipid called PI(3)P, killing cancer cells and slowing disease progression significantly.
UTEP researchers developed a portable device that can detect colorectal and prostate cancer quickly and accurately, reducing the need for costly instruments. The device is low-cost, sensitive, and analyzes samples in just an hour.
A new study from the University of Texas at Arlington suggests that analyzing RNA in urine can show changes in cell types, revealing early signs of cancer and other diseases. This method could help clinicians detect problems earlier when they are more easily treated without invasive procedures.
The UCLA Urology department has been awarded $6 million to continue the IMPACT program, providing comprehensive prostate cancer treatment for underinsured and uninsured Californians. The program has helped over 2,300 men receive treatment services since its inception.
A new study suggests that a healthy diet may help keep low-grade prostate cancer from progressing to more aggressive states in men undergoing active surveillance. The research team led by Johns Hopkins Medicine found that a reduced risk of prostate cancer progression is associated with a healthy diet.
Researchers at Duke University Medical Center found that Black men with metastatic prostate cancer have the greatest survival benefit from sipuleucel-T immunotherapy, possibly due to a genetic variant that encourages an inflammatory response. The study could lead to targeted treatment for patients who will benefit most
A groundbreaking study has demonstrated the clinical success of a new nanoparticle-based, laser-guided therapy for prostate cancer treatment. The therapy successfully eliminated cancerous cells in 73% of patients after 12 months while preserving key functions and side effects.
Researchers found that fermented black garlic extract reduced tumor aggressiveness parameters, including cell proliferation, without affecting normal prostate cells. The extract altered key signaling pathways related to inflammation, suggesting its potential as a dietary supplement to prevent or slow down prostate cancer progression.
Researchers identified three genetic regions strongly associated with increased prostate incidence in a diverse group of African men. The study, the largest of its kind in Africa, may lead to new treatment possibilities and refined screening methods.
Researchers analyzed changes in 72 pairs of microRNAs in patients' blood extracellular vesicles before and after radical prostatectomy, identifying significant changes in 11 miRNA ratios. The study suggests a potential new biomarker for monitoring treatment efficacy and predicting cancer relapse.
Recent clinical trials of neoadjuvant therapy before radical prostatectomy, such as the ACDC-RP trial, have struggled to show significant survival benefits. Researchers recommend maximal androgen blockade with an androgen receptor pathway inhibitor as the 'backbone' of neoadjuvant therapy trials.
A recent study published in The Prostate used genetically modified mice to investigate the relationship between gut dysbiosis and prostate cancer. The researchers found that both humans and mice exhibited marked differences in their gut microbiome composition, with certain bacteria positively associated with prostate cancer. Additional...
A non-invasive blood test measuring circulating tumor cells can predict treatment response, disease progression, and overall survival in men with metastatic prostate cancer. Patients with more CTCs had shorter median survival lengths and a greater risk of death.
Researchers at Michigan Medicine have discovered a new subtype of aggressive prostate cancer and identified a potential degrader to target it. The study found that a genetic alteration in the CDK12 gene drives cancer development, and a degrader targeting this gene shows promise in destroying cancer cells.
Researchers propose reevaluating nomenclature for low-grade prostate cancer, a condition that rarely metastasizes or causes symptoms. This shift aims to balance detection with treatment to reduce harms of overdiagnosis and overtreatment.
A multi-center phase III trial found photon- and proton-based radiation therapies to be similarly safe and effective in treating low- and intermediate-risk prostate cancer. Patients treated with either IMRT or proton therapy reported no significant differences in quality of life, tumor control, or progression-free survival.
UCLA investigators presented data on chemoradiotherapy in rectal cancer, MRI-guided radiotherapy for prostate cancer, and symptom self-reporting during treatment. Researchers developed a predictive model to identify patients most likely to respond to chemoradiotherapy in rectal cancer.
A new study has found that baseline testosterone, age, and duration of ADT are key predictors of testosterone recovery. The researchers developed a nomogram to estimate recovery times based on patient-specific characteristics, providing valuable insights for improving patient outcomes.
Researchers at Cold Spring Harbor Laboratory create a roadmap of how prostate cancer spreads throughout the body, showing that aggressive cells seed cancer's rare migrations to bones, liver, lungs, and lymph nodes. The new technology offers a clearer picture of cancer spread and could lead to more targeted therapeutics.
A new study by the University of Eastern Finland found that pro-inflammatory macrophages can transform prostate cancer cells into stem-like cells, making them resistant to treatment. The study reveals that these immune cells secrete factors that increase the expression of stem cell markers in prostate cancer cells.
A study published in Nature Communications found that the MYC gene is a common culprit driving prostate cancer progression. The research reveals how MYC activation attracts immune cells to the tumor but later helps hide it from immune detection, making it undetectable.
A new prostate biopsy technique, transperineal biopsy, has been shown to lower the risk of infection compared to traditional biopsies. The PREVENT trial found no infections among men who underwent the transperineal procedure, while those with traditional transrectal biopsies had a 1.6% infection rate despite receiving antibiotics.
A new study found that immunotherapy can effectively treat prostate cancer in men with a specific genetic type, slowing disease progression by four to 33 months. This treatment approach may be beneficial for approximately 4-5% of patients, who experience significant cancer control.
A new study by Michigan Medicine found that the Inflation Reduction Act's limit on Medicare Part D spending leads to significant savings for cancer patients prescribed oral chemotherapy. The average annual cost for these medications decreased from $11,284 in 2023 to $3,927 in 2024, resulting in median cost savings of $7,260.
A new study has identified NSD2 as a fundamental factor in early stages of prostate cancer development, found to alter androgen receptor function leading to rapid cell division and growth. The study may suggest a new way to therapeutically target prostate cancer by targeting the epigenetic component NSD2.
A new AI model generates detailed images of cancer tissue that imitate what its staining would look like, reducing the need for resource-intensive lab analyses. The VirtualMultiplexer uses contrastive unpaired translation to create accurate virtual pictures of diagnostic tissue colorations.
Researchers discovered that low testosterone levels stimulate cancer cell proliferation, while high doses cause differentiation and suppress growth. This finding could help physicians select patients for bi-polar androgen therapy, a technique using monthly high-dose testosterone injections.
Rates of prostate cancer across Europe more than doubled from 1990 to 2017, with highest increases in northern Europe, France, and the Baltic countries. Death rates were lower, sparking concerns about overdiagnosis and unnecessary treatment, emphasizing the need for carefully planned screening programs.
Researchers developed a novel compound to target prostate cancer using radioactive atom astatine-211, potentially overcoming issues with previous compounds like deastatination. The study found high accumulation in tumors and low accumulation in vital organs, highlighting the potential of this new compound for targeted alpha therapy.
Researchers at HSE University discovered that the microRNA overexpression method may produce incorrect results due to errors in Dicer enzyme cleavage. This can lead to the formation of miRNA isoforms that target unintended genes, resulting in inaccurate conclusions about molecular mechanisms.
Aston University researcher has developed a new method of analysing crystals in dehydrated blood samples using polarisation-based image reconstruction technique. The technique showed a 90% accuracy rate for early diagnosis and classification of cancer, making it less traumatic and risky for patients.
Researchers at Flinders University and University of South Australia have discovered a potential breakthrough in treating the most aggressive forms of prostate cancer using CDKI-73, a novel drug inhibitor. The study found that CDKI-73 effectively blocks the growth of prostate cancer cells while sparing normal cells.
Researchers investigated the connection between androgen deprivation therapy for prostate cancer and Alzheimer's disease. They found that ADT can exacerbate cognitive decline by increasing brain immune cell infiltration, but a combination with Natalizumab improved integrity of the blood-brain barrier and reduced inflammation.
A phase II clinical trial found that olaparib, a precision oncology drug, can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations. The study showed that 13 participants, including all 11 with BRCA2 mutations, had a decrease in PSA of at least 50% after treatment.
A new study published in Nature Medicine shows that precision therapy can improve survival for men with metastatic castration-resistant prostate cancer. The treatment, which involves analyzing the genetic profile of the tumor, has been shown to be more effective than chemotherapy in patients whose tumors have specific mutations.
Researchers at Mount Sinai have identified a new class of RNAs packed into tiny particles known as extracellular vesicles that could revolutionize how cancer and other diseases are diagnosed. These molecules undergo changes when cancer is present, suggesting their potential as biomarkers for detecting prostate cancer.
A new study suggests that MRI scans can help doctors identify patients with more aggressive prostate cancer, allowing for earlier treatment or active surveillance. The research found that suspicious lesions on an MRI test were associated with a higher risk of advanced disease in five years.
A new deep learning model detects clinically significant prostate cancer on MRI with performance comparable to experienced abdominal radiologists. The model's prediction can be used as an adjunct to improve diagnostic performance and reduce false positives.
Researchers from the University of Sheffield have developed a new form of immunotherapy using nanoparticles that delays the onset of resistance to hormone therapy in prostate cancer. This innovative approach stimulates immune cells called T cells to attack cancer cells, marking a significant breakthrough in treating prostate cancer.
Researchers have developed an AI-based system that can predict the risk of prostate cancer more accurately than traditional methods. The new tool combines MRI images and deep learning to identify low-risk patients who may not need a biopsy, potentially sparing them from unnecessary procedures and reducing complications.
Researchers highlight acute need for mental health services and support for men with prostate cancer. The study found that 15% of prostate cancer patients started anti-anxiety and antidepression medications at diagnosis, while only 6% sought help from mental health services.
A new study from Michigan Medicine suggests that inhibiting the SWI/SNF epigenetic complex can therapeutically target oncogenic transcription factors. The research, led by Arul Chinnaiyan, builds on previous work to find genetic vulnerabilities in transcription factor-driven cancers.
A recent review article highlights the importance of genetic testing for men carrying BRCA1 or BRCA2 mutations, which increase their risk of developing prostate, pancreatic, and breast cancers. The guidelines emphasize the need for personalized cancer screening to help identify high-risk individuals.
Researchers at UCLA Health Sciences identified three distinct patient preference-based profiles among men with low-risk prostate cancer. Despite differences in preferences, physician recommendations played a crucial role in determining treatment choices. The study highlights the need for better integrating patient preferences into trea...
Researchers found that lower doses of radiopharmaceutical therapy approaches for metastatic castrate-resistant prostate cancer were just as effective as the standard dose, with better tolerability among patients. The study showed improved PSA response rates and comparable median overall survival in both groups.
A recent study published in Journal of Clinical Oncology has shown that the Stockholm3 prostate cancer blood test is equally effective in detecting clinically significant cancer across different ethnic groups, including African Americans and Asians. The test reduces unnecessary biopsies by 45% while maintaining high detection rates.
Researchers from Radboud University Medical Center discuss the potential of using early on-treatment circulating tumor DNA measurements as a response assessment for metastatic castration-resistant prostate cancer. The detection of ctDNA at baseline and 4-weeks after treatment initiation can predict response durability to first-line ARPIs.
Researchers found that out-of-pocket costs for additional tests, including MRI and biopsies, are common and increasing among privately insured men with high PSA results. The median cost rose substantially between 2010-2020, deterring patients from undergoing recommended screening.
A cross-sectional study found that men from disadvantaged neighborhoods had higher stress-related gene expression in their prostate tumors. This association suggests a potential link between neighborhood factors and aggressive prostate cancer.
A study found that living in disadvantaged neighborhoods is associated with higher stress-related gene activity, which could contribute to aggressive prostate cancer in African American men. The research also linked five genes related to inflammation to an increased risk of prostate cancer.
Researchers identified two risk factors that indicate higher risk of aggressive prostate cancer, including high PSA levels and positive biopsy samples. Patients with these indicators are at increased risk of adverse pathology, early recurrence, and death.
Researchers developed a novel liquid biopsy technique to monitor disease evolution in metastatic prostate cancer patients. The method analyzes DNA and RNA in circulating extracellular vesicles, capturing tumor genomics and transcriptomic changes.